GRP and prostate carcinoma: Thus, McInnes et al. reported the therapeutic efficacy of 67Cu-CuSarbisPSMA in prostate cancer therapy [94], 67Cu-radiolabeled bombesin antagonist peptide [67Cu]Cu-SAR-BBN was effective in PC-3 tumor therapy, as reported by Huynh et al. [97].